RE: Deleted Post29 Nov 2024 00:38
After doing my best to keep away from this toxic site, I thought I would have a look to see what was being said following the latest developments; I wish i had not bothered.
This side is riddled with mischievous and manipulative posts; it has become pointless and no longer (if indeed it ever was) offers any genuine insight. The only value it brings is picking out the occasional legitimate link to news. (providing readers are able to filter it out from the links that are not relevant and only shared for maniplative purposes)
I will admit that I lost the love for Hemo for a few months; I disposed of my shares and kept away from this board. However, i revinvested at 1.2p and 1.5p over the last few months and I'm excited in repsect of the commencement of trials.
I wish the company all the luck in the world to go with the immense skill and talent that they bring. I hope the company are successful at raising many millions in the coming weeks and months and that I/we are joined by some serious big investors. I'm not naive, I would expect that significant new investors will be given a good entry price; in the short term it may be regarded as diluting existing holders, but if the investment in significant enough I think it should be regarded as a win for exisiting holders.
The current market Cap / value for Hemo is influenced by a few key things:
(1) IT's clincial assets - the progress it has made in the lab and getting CAR-T, CBR and CDX to where they are now
(2) The potential rewards that success in Phase 1 / 2 may bring
(3) The fact that the company does not have large cash reserves; this is factored into the current valuation. If the company is successful in attracting significant new investment this will add significant value to the company as it will no longer be cash poor. For me, this should hopefully limit the dilution.
The bottom line here, is that (1) Hemo need to successully attract new investment and (2) a huge amount is riding on the outcome of the clinical trials.
Good luck all